Atara Biotherapeutics, Inc. cotiza a 9.12 USD y tiene una capitalización bursátil de $92M. En los últimos 12 meses ha facturado $6M con un margen de flujo de caja libre del -42.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-b…
| Métrica | ATRA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 29.7% | -38.6% | +68.3% |
| Net Margin | 27.1% | -33.6% | +60.6% |
| FCF Margin | -42.2% | -13.9% | -28.3% |
| ROE | — | -40.4% | — |
| ROA | 161.5% | -32.0% | +193.5% |
| Current Ratio | 0.82 | 2.84 | -2.02 |
| Debt / Equity | — | 0.28 | — |